Cooper C, Atkinson EJ, Jacobsen SJ, et al.. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001–1005.

• Crossref
• PubMed
Cooper C, Atkinson EJ, Jacobsen SJ, . Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001–1005.831744510.1093/oxfordjournals.aje.a116756)| false
• Search Google Scholar
• Export Citation

Hillner BE, Ingle JN, Chlebowski RT, et al.. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042–4057.

• Crossref
• PubMed
Hillner BE, Ingle JN, Chlebowski RT, . American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042–4057.10.1200/JCO.2003.08.01712963702)| false
• Search Google Scholar
• Export Citation

Tham YL, Sexton K, Kramer R, et al.. The adherence of practice guidelines in the assessment of bone health in women with chemotherapy-induced amenorrhea. San Antonio Breast Cancer Symposium 2005, Abstract # 6070.

• PubMed
Tham YL, Sexton K, Kramer R, . The adherence of practice guidelines in the assessment of bone health in women with chemotherapy-induced amenorrhea. San Antonio Breast Cancer Symposium 2005, Abstract # 6070.)| false
• Search Google Scholar
• Export Citation

Green AD, Colon-Emeric CS, Bastian L. Does this woman have osteoporosis? JAMA 2004;292:2890–900.

• Crossref
• PubMed
Green AD, Colon-Emeric CS, Bastian L. Does this woman have osteoporosis? JAMA 2004;292:2890–900.1559892110.1001/jama.292.23.2890)| false
• Search Google Scholar
• Export Citation

Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:529–541.

• Crossref
• PubMed
Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:529–541.10.7326/0003-4819-137-6-200209170-0001512230356)| false
• Search Google Scholar
• Export Citation

Raisz LG. Clinical practice: Screening for osteoporosis. N Engl J Med 2005;353:164–171.

• Crossref
• PubMed
Raisz LG. Clinical practice: Screening for osteoporosis. N Engl J Med 2005;353:164–171.1601488610.1056/NEJMcp042092)| false
• Search Google Scholar
• Export Citation

Kanis JA, McCloskey EV, Powles T, et al.. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999;79:1179–1181.

• Crossref
• PubMed
Kanis JA, McCloskey EV, Powles T, . A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999;79:1179–1181.1009875510.1038/sj.bjc.6690188)| false
• Search Google Scholar
• Export Citation

Chen Z, Maricic M, Bassford TL, et al.. Fracture risk among breast cancer survivors: results from the Women’s Health Initiative Observational Study. Arch Intern Med 2005;165: 552–558.

• Crossref
• PubMed
Chen Z, Maricic M, Bassford TL, . Fracture risk among breast cancer survivors: results from the Women’s Health Initiative Observational Study. Arch Intern Med 2005;165: 552–558.1576753210.1001/archinte.165.5.552)| false
• Search Google Scholar
• Export Citation

Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 2000;15:183–187.

• Crossref
• PubMed
Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 2000;15:183–187.10.1359/jbmr.2000.15.2.18310703919)| false
• Search Google Scholar
• Export Citation

Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002;288:1889–1897.

• Crossref
• PubMed
Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002;288:1889–1897.10.1001/jama.288.15.188912377088)| false
• Search Google Scholar
• Export Citation

Siris ES, Miller PD, Barrett-Connor E, et al.. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the National Osteoporosis Risk Assessment. JAMA 2001;286: 2815–2822.

• Crossref
• PubMed
Siris ES, Miller PD, Barrett-Connor E, . Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the National Osteoporosis Risk Assessment. JAMA 2001;286: 2815–2822.10.1001/jama.286.22.281511735756)| false
• Search Google Scholar
• Export Citation

Miller PD, Barlas S, Brenneman SK, et al.. An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 2004;164:1113–1120.

• Crossref
• PubMed
Miller PD, Barlas S, Brenneman SK, . An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 2004;164:1113–1120.10.1001/archinte.164.10.111315159269)| false
• Search Google Scholar
• Export Citation

Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, et al.. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000;26:505–511.

• Crossref
• PubMed
Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, . Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000;26:505–511.1077359110.1016/S8756-3282(00)00248-9)| false
• Search Google Scholar
• Export Citation

Christgau S. Circadian variation in serum CrossLaps concentration is reduced in fasting individuals. Clin Chem 2000;46:431.

• Crossref
• PubMed
Christgau S. Circadian variation in serum CrossLaps concentration is reduced in fasting individuals. Clin Chem 2000;46:431.10.1093/clinchem/46.3.431a10702538)| false
• Search Google Scholar
• Export Citation

Eastell R, Mallinak N, Weiss S, et al.. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 2000;15: 594–598.

• Crossref
• PubMed
Eastell R, Mallinak N, Weiss S, . Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 2000;15: 594–598.10.1359/jbmr.2000.15.3.59410750575)| false
• Search Google Scholar
• Export Citation

Clowes JA, Hannon RA, Yap TS, et al.. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002;30:886–890.

• Crossref
• PubMed
Clowes JA, Hannon RA, Yap TS, . Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002;30:886–890.10.1016/S8756-3282(02)00728-712052458)| false
• Search Google Scholar
• Export Citation

Chestnut CH, Bell NH, Clark GS, et al.. Hormone replacement therapy in postmenopausal women: Urinary Ntelopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997; 102:29–37.

• Crossref
• PubMed
Chestnut CH, Bell NH, Clark GS, . Hormone replacement therapy in postmenopausal women: Urinary Ntelopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997; 102:29–37.10.1016/S0002-9343(96)00387-79209198)| false
• Search Google Scholar
• Export Citation

Ravn P, Clemmesen B, Christinasen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999;24: 237–244.

• Crossref
• PubMed
Ravn P, Clemmesen B, Christinasen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999;24: 237–244.10.1016/S8756-3282(98)00183-510071916)| false
• Search Google Scholar
• Export Citation

Mouritzen, Buclin T, Cosma Rochat M, et al.. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in health volunteers. J Bone Miner Res 2002; 17:1478–1485.

• Crossref
• PubMed
Mouritzen, Buclin T, Cosma Rochat M, . Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in health volunteers. J Bone Miner Res 2002; 17:1478–1485.10.1359/jbmr.2002.17.8.147812162502)| false
• Search Google Scholar
• Export Citation

NIH Consensus Statement. Optimal calcium intake. 1994;12:1–31.

• PubMed
NIH Consensus Statement. Optimal calcium intake. 1994;12:1–31.)| false
• Search Google Scholar
• Export Citation

Yates AA, Schlicker SA, Suitor CW. Dietary reference intakes: the new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J Am Diet Assoc 1998;98:699–706.

• Crossref
• PubMed
Yates AA, Schlicker SA, Suitor CW. Dietary reference intakes: the new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J Am Diet Assoc 1998;98:699–706.10.1016/S0002-8223(98)00160-69627630)| false
• Search Google Scholar
• Export Citation

Lips P. Vitamin D deficiency and secondary hyperparathyriodism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocrine Rev 2001;22: 477–501.

• Crossref
• PubMed
Lips P. Vitamin D deficiency and secondary hyperparathyriodism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocrine Rev 2001;22: 477–501.10.1210/edrv.22.4.043711493580)| false
• Search Google Scholar
• Export Citation

Chapuy MC, Arlot ME, Duboeuf F, et al.. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637–1642.

• Crossref
• PubMed
Chapuy MC, Arlot ME, Duboeuf F, . Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637–1642.10.1056/NEJM1992120332723051331788)| false
• Search Google Scholar
• Export Citation

Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670–676.

• Crossref
• PubMed
Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670–676.10.1056/NEJM1997090433710039278463)| false
• Search Google Scholar
• Export Citation

Grant AM, Avenell A, Campbell MK, et al.. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebocontrolled trial. Lancet 2005;365:1621–1628.

• Crossref
• PubMed
Grant AM, Avenell A, Campbell MK, . Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebocontrolled trial. Lancet 2005;365:1621–1628.10.1016/S0140-6736(05)63013-915885294)| false
• Search Google Scholar
• Export Citation

Porthouse J, Cockayne S, King C, et al.. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005;330:1003.

• Crossref
• PubMed
Porthouse J, Cockayne S, King C, . Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005;330:1003.1586082710.1136/bmj.330.7498.1003)| false
• Search Google Scholar
• Export Citation

Jackson RD, LaCroix AZ, Gass M, et al.. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006:354;339.

• Crossref
• PubMed
Jackson RD, LaCroix AZ, Gass M, . Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006:354;339.10.1056/NEJMoa05521816481635)| false
• Search Google Scholar
• Export Citation

Cummings SR, Karpf DB, Harris F et al.. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs Am J Med 2002;112:281–289.

• Crossref
• PubMed
Cummings SR, Karpf DB, Harris F . Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs Am J Med 2002;112:281–289.1189336710.1016/S0002-9343(01)01124-X)| false
• Search Google Scholar
• Export Citation

Ettinger B, Black DM, Mitlak BH, et al.. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282: 637–645.

• Crossref
• PubMed
Ettinger B, Black DM, Mitlak BH, . Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282: 637–645.10.1001/jama.282.7.63710517716)| false
• Search Google Scholar
• Export Citation

Black DM, Cummings SR, Karpf DB. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–1541.

• Crossref
• PubMed
Black DM, Cummings SR, Karpf DB. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–1541.10.1016/S0140-6736(96)07088-28950879)| false
• Search Google Scholar
• Export Citation

McClung MR, Geusens P, Miller PD, et al.. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344: 333–340.

• Crossref
• PubMed
McClung MR, Geusens P, Miller PD, . Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344: 333–340.10.1056/NEJM20010201344050311172164)| false
• Search Google Scholar
• Export Citation

Delmas PD, Recker RR, Chesnut CH, et al.. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporosis Int 2004;15:792–798.

• Crossref
• PubMed
Delmas PD, Recker RR, Chesnut CH, . Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporosis Int 2004;15:792–798.10.1007/s00198-004-1602-915071723)| false
• Search Google Scholar
• Export Citation

Thiebaud D, Burckhardt P, Melchior J, et al.. Two years’ effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in postmenopause. Osteoporos Int 1994;4:76–83.

• Crossref
• PubMed
Thiebaud D, Burckhardt P, Melchior J, . Two years’ effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in postmenopause. Osteoporos Int 1994;4:76–83.10.1007/BF016232278003844)| false
• Search Google Scholar
• Export Citation

Thiebaud D, Burckhardt P, Kriegbaum H, et al.. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997;103:298–307.

• Crossref
• PubMed
Thiebaud D, Burckhardt P, Kriegbaum H, . Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997;103:298–307.938212210.1016/S0002-9343(97)00249-0)| false
• Search Google Scholar
• Export Citation

Fuleihan Gel -H, Salamoun M, Mourad YA, et al.. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 2005;90: 3209–3214.

• Crossref
• PubMed
Fuleihan Gel-H, Salamoun M, Mourad YA, . Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 2005;90: 3209–3214.10.1210/jc.2004-144415769994)| false
• Search Google Scholar
• Export Citation

Swenson KK, Henly SJ, Shapiro AC, Schroeder LM. Interventions to prevent loss of bone mineral density in women receiving chemotherapy for breast cancer. Clin J Oncol Nurs 2005;9:177–184.

• Crossref
• PubMed
Swenson KK, Henly SJ, Shapiro AC, Schroeder LM. Interventions to prevent loss of bone mineral density in women receiving chemotherapy for breast cancer. Clin J Oncol Nurs 2005;9:177–184.1585316110.1188/05.CJON.177-184)| false
• Search Google Scholar
• Export Citation

Smith MR, McGovern FJ, Zeitman AL, et al.. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948–955.

• Crossref
• PubMed
Smith MR, McGovern FJ, Zeitman AL, . Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948–955.10.1056/NEJMoa01084511575286)| false
• Search Google Scholar
• Export Citation

Diamond TH, Winters J, Smith A, et al.. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001;92:1444–1450.

• Crossref
• PubMed
Diamond TH, Winters J, Smith A, . The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001;92:1444–1450.10.1002/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M11745221)| false
• Search Google Scholar
• Export Citation

Smith MR, Eastham J, Gleason DM, et al.. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008–2012.

• Crossref
• PubMed
Smith MR, Eastham J, Gleason DM, . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008–2012.10.1097/01.ju.0000063820.94994.9512771706)| false
• Search Google Scholar
• Export Citation

Saad F, Gleason DM, Murray R, et al.. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458–1468.

• Crossref
• PubMed
Saad F, Gleason DM, Murray R, . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458–1468.10.1093/jnci/94.19.145812359855)| false
• Search Google Scholar
• Export Citation

Hortobagyi GN, Theriault RL, Porter L, et al.. Efficacy of pamidronate in reducing skeletal-related complications in patients with breast cancer and lytic bone lesions. N Engl J Med 1996;335:1785–1791.

• Crossref
• PubMed
Hortobagyi GN, Theriault RL, Porter L, . Efficacy of pamidronate in reducing skeletal-related complications in patients with breast cancer and lytic bone lesions. N Engl J Med 1996;335:1785–1791.10.1056/NEJM1996121233524018965890)| false
• Search Google Scholar
• Export Citation

Hortobagyi GN, Theriault RL, Lipton A, et al.. for the Protocol 19 Aredia Breast Cancer Study Group. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998;16:2038–2044.

• Crossref
• PubMed
Hortobagyi GN, Theriault RL, Lipton A, . for the Protocol 19 Aredia Breast Cancer Study Group. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998;16:2038–2044.10.1200/JCO.1998.16.6.20389626201)| false
• Search Google Scholar
• Export Citation

Lipton A, Demers L, Curley E, et al.. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021–206.

• Crossref
• PubMed
Lipton A, Demers L, Curley E, . Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021–206.10.1016/S0959-8049(98)00277-910070304)| false
• Search Google Scholar
• Export Citation

Theriault RL, Lipton A, Hortobagyi GN, et al..: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomised, placebocontrolled trial. J Clin Oncol 1999;17:846–854.

• Crossref
• PubMed
Theriault RL, Lipton A, Hortobagyi GN, .: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomised, placebocontrolled trial. J Clin Oncol 1999;17:846–854.10.1200/JCO.1999.17.3.84610071275)| false
• Search Google Scholar
• Export Citation

Neer RM, Arnaud CD, Zanchetta JR, et al.. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–1441.

• Crossref
• PubMed
Neer RM, Arnaud CD, Zanchetta JR, . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–1441.1134680810.1056/NEJM200105103441904)| false
• Search Google Scholar
• Export Citation

Van Poznak C, Sauter S. Clinical management of osteoporosis in women with a history of breast cancer. Cancer 2005;104:443–456.

• Crossref
• PubMed
Van Poznak C, Sauter S. Clinical management of osteoporosis in women with a history of breast cancer. Cancer 2005;104:443–456.10.1002/cncr.2120115968687)| false
• Search Google Scholar
• Export Citation

Meunier PJ, Roux C, Seeman E, et al.. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350: 459–468.

• Crossref
• PubMed
Meunier PJ, Roux C, Seeman E, . The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350: 459–468.10.1056/NEJMoa02243614749454)| false
• Search Google Scholar
• Export Citation

Reginster JY, Seeman E, De Vernejoul MC, et al.. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study J Clin Endocrinol Metab 2005;90:2816–2822.

• Crossref
• PubMed
Reginster JY, Seeman E, De Vernejoul MC, . Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study J Clin Endocrinol Metab 2005;90:2816–2822.10.1210/jc.2004-177415728210)| false
• Search Google Scholar
• Export Citation

Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006:24;675

• Crossref
• PubMed
Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006:24;67510.1200/JCO.2005.02.351516446340)| false
• Search Google Scholar
• Export Citation

Love RR, Mazess RR, Barden HS, et al.. Effects of tamoxefen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852–856.

• Crossref
• PubMed
Love RR, Mazess RR, Barden HS, . Effects of tamoxefen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852–856.10.1056/NEJM1992032632613021542321)| false
• Search Google Scholar
• Export Citation

Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490–495.

• Crossref
• PubMed
Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490–495.1528034710.1001/jama.292.4.490)| false
• Search Google Scholar
• Export Citation

Bekker PJ, Holloway DL, Rasmussen AS, et al.. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059–1066.

• Crossref
• PubMed
Bekker PJ, Holloway DL, Rasmussen AS, . A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059–1066.1517698710.1359/JBMR.040305)| false
• Search Google Scholar
• Export Citation

McClung MR, Lewiecki EM, Cohen SB, et al.. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821–831.

• Crossref
• PubMed
McClung MR, Lewiecki EM, Cohen SB, . Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821–831.1649539410.1056/NEJMoa044459)| false
• Search Google Scholar
• Export Citation

Goodwin PJ, Ennis M, Pritchard KI, et al.. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365–2370.

• Crossref
• PubMed
Goodwin PJ, Ennis M, Pritchard KI, . Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365–2370.10.1200/JCO.1999.17.8.236510561298)| false
• Search Google Scholar
• Export Citation

Fornier MN, Modi S, Panageas KS, et al.. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005;104: 1575–1579.

• Crossref
• PubMed
Fornier MN, Modi S, Panageas KS, . Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005;104: 1575–1579.1613417810.1002/cncr.21385)| false
• Search Google Scholar
• Export Citation

Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med 2000;343:1086–1094.

• Crossref
• PubMed
Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med 2000;343:1086–1094.1102774410.1056/NEJM200010123431506)| false
• Search Google Scholar
• Export Citation

Shapiro CL, Phillips G, Van Poznak CH, et al.. Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure. Breast Cancer Res Treat 2005;90:41–46.

• Crossref
• PubMed
Shapiro CL, Phillips G, Van Poznak CH, . Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure. Breast Cancer Res Treat 2005;90:41–46.1577052510.1007/s10549-004-2625-9)| false
• Search Google Scholar
• Export Citation

Anders CK, Snyder SA, Barrier RC, et al.. Inhibin A and B as predictive markers for chemotherapy-induced premature ovarian failure (POF) among premenopausal women with early stage breast cancer (ESBC). San Antonio Breast Cancer Symposium 2005. Abstract #1027.

• PubMed
Anders CK, Snyder SA, Barrier RC, . Inhibin A and B as predictive markers for chemotherapy-induced premature ovarian failure (POF) among premenopausal women with early stage breast cancer (ESBC). San Antonio Breast Cancer Symposium 2005. Abstract #1027.)| false
• Export Citation

Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19:3306–3311.

• Crossref
• PubMed
Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19:3306–3311.10.1200/JCO.2001.19.14.330611454877)| false
• Search Google Scholar
• Export Citation

Powles TJ, McCloskey E, Paterson AH, et al.. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998; 90:704–708.

• Crossref
• PubMed
Powles TJ, McCloskey E, Paterson AH, . Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998; 90:704–708.958666810.1093/jnci/90.9.704)| false
• Search Google Scholar
• Export Citation

Saarto T, Blomqvist C, Valimaki M, et al.. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997;15:1341–1347.

• Crossref
• PubMed
Saarto T, Blomqvist C, Valimaki M, . Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997;15:1341–1347.919332510.1200/JCO.1997.15.4.1341)| false
• Search Google Scholar
• Export Citation

Delmas PD, Balena R, Confravreux E, et al.. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a doubleblind, placebo-controlled study. J Clin Oncol 1997;15: 955–962.

• Crossref
• PubMed
Delmas PD, Balena R, Confravreux E, . Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a doubleblind, placebo-controlled study. J Clin Oncol 1997;15: 955–962.10.1200/JCO.1997.15.3.9559060533)| false
• Search Google Scholar
• Export Citation

Howell A, on behalf of the ATAC Trialists’ Group A. ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) completed treatment analysis: Anastrozole demonstrates superior efficacy and tolerability compared with tamoxifen. 2004 San Antonio Breast Cancer symposium, Abstract #1.

• PubMed
Howell A, on behalf of the ATAC Trialists’ Group A. ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) completed treatment analysis: Anastrozole demonstrates superior efficacy and tolerability compared with tamoxifen. 2004 San Antonio Breast Cancer symposium, Abstract #1.)| false
• Export Citation

Thurlimann B, Keshaviah A, Coates AS, et al.. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747–2757.

• Crossref
• PubMed
Thurlimann B, Keshaviah A, Coates AS, . A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747–2757.1638206110.1056/NEJMoa052258)| false
• Search Google Scholar
• Export Citation

Coombes RC, Hall E, Gibson LJ et al.. Intergroup Exemestane Study: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–1092.

• Crossref
• PubMed
Coombes RC, Hall E, Gibson LJ . Intergroup Exemestane Study: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–1092.10.1056/NEJMoa04033115014181)| false
• Search Google Scholar
• Export Citation

Coombes RC, Hall E, Snowdon CF, et al.. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. 2004 San Antonio Breast Cancer Symposium, Abstract #3.

• PubMed
Coombes RC, Hall E, Snowdon CF, . The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. 2004 San Antonio Breast Cancer Symposium, Abstract #3.)| false
• Export Citation

Goss PE, Ingle JN, Martino S, et al.. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–1802.

• Crossref
• PubMed
Goss PE, Ingle JN, Martino S, . A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–1802.10.1056/NEJMoa03231214551341)| false
• Search Google Scholar
• Export Citation

Gnant M, Jakesz R, Minerritsch B, et al.. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopauasl breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole vs. gosereline plus tamoxifen. San Antonio Breast Cancer Symposium 2004, Abstract #6.

• PubMed
Gnant M, Jakesz R, Minerritsch B, . Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopauasl breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole vs. gosereline plus tamoxifen. San Antonio Breast Cancer Symposium 2004, Abstract #6.)| false
• Export Citation

Brufsky A, Harker W, Beck J, et al.. Zoledronic acid effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women with early breast cancer receiving adjuvant Letrozole: 12 mos BMD results of the Z-FAST trial. 2005 ASCO Annual Meeting, Abstract #533.

• PubMed
Brufsky A, Harker W, Beck J, . Zoledronic acid effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women with early breast cancer receiving adjuvant Letrozole: 12 mos BMD results of the Z-FAST trial. 2005 ASCO Annual Meeting, Abstract #533.)| false
• Export Citation

Powles T, McCloskey E, Kurkilahti M, et al.. Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial. 2004 ASCO Annual Meeting, Abstract #528.

• PubMed
Powles T, McCloskey E, Kurkilahti M, . Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial. 2004 ASCO Annual Meeting, Abstract #528.)| false
• Export Citation

Mittan D, Lee S, Miller E, Perez RC, et al.. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002;87: 3656–3661.

• Crossref
• PubMed
Mittan D, Lee S, Miller E, Perez RC, . Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002;87: 3656–3661.1216149110.1210/jcem.87.8.8782)| false
• Search Google Scholar
• Export Citation

Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154–164.

• Crossref
• PubMed
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154–164.1564757810.1056/NEJMoa041943)| false
• Search Google Scholar
• Export Citation

Smith MR, Lee WC, Brandman J, et al.. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:7897–903.

• Crossref
• PubMed
Smith MR, Lee WC, Brandman J, . Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:7897–903.10.1200/JCO.2004.00.690816258089)| false
• Search Google Scholar
• Export Citation

Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:3841–3846.

• Crossref
• PubMed
Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:3841–3846.1529231510.1210/jc.2003-032058)| false
• Search Google Scholar
• Export Citation

Brown JE, Cook RJ, Major P, et al.. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97:59–69.

• Crossref
• PubMed
Brown JE, Cook RJ, Major P, . Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97:59–69.1563238110.1093/jnci/dji002)| false
• Search Google Scholar
• Export Citation

Dearnaley DP, Sydes MR, Mason MD, et al.. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003;95:1300–1311.

• Crossref
• PubMed
Dearnaley DP, Sydes MR, Mason MD, . A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003;95:1300–1311.1295308410.1093/jnci/djg038)| false
• Search Google Scholar
• Export Citation

Kang Y, Siegel PM, Shu W et al.. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537–549.

• Crossref
• PubMed
Kang Y, Siegel PM, Shu W . A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537–549.10.1016/S1535-6108(03)00132-612842083)| false
• Search Google Scholar
• Export Citation

Yin JJ, Selander K, Chirgwin JM, et al.. TGF-signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103: 197–206.

• Crossref
• PubMed
Yin JJ, Selander K, Chirgwin JM, . TGF-signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103: 197–206.10.1172/JCI35239916131)| false
• Search Google Scholar
• Export Citation

Yang YA, Dukhanina O, Tang B, et al.. Lifetime exposure to a soluble TGF- antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002;109:1607–1615.

• Crossref
• PubMed
Yang YA, Dukhanina O, Tang B, . Lifetime exposure to a soluble TGF- antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002;109:1607–1615.10.1172/JCI20021533312070308)| false
• Search Google Scholar
• Export Citation

Kang Y, He W, Tulley S, et al.. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A 2005;102:13909–13914.

• Crossref
• PubMed
Kang Y, He W, Tulley S, . Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A 2005;102:13909–13914.10.1073/pnas.050651710216172383)| false
• Search Google Scholar
• Export Citation

Muraoka RS, Dumont N, Ritter CA et al.. Blockade of TGF- inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest. 2002;109:1551–1559.

• Crossref
• PubMed
Muraoka RS, Dumont N, Ritter CA . Blockade of TGF- inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest. 2002;109:1551–1559.1207030210.1172/JCI0215234)| false
• Search Google Scholar
• Export Citation

Uhl M, Aulwurm S, Wischhusen J, et al.. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004;64:7954–7961.

• Crossref
• PubMed
Uhl M, Aulwurm S, Wischhusen J, . SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004;64:7954–7961.10.1158/0008-5472.CAN-04-101315520202)| false
• Search Google Scholar
• Export Citation

Hayashi T, Hideshima T, Nguyen AN, et al.. Transforming growth factor beta receptor I kinase inhibitor downregulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 2004;10:7540–7546.

• Crossref
• PubMed
Hayashi T, Hideshima T, Nguyen AN, . Transforming growth factor beta receptor I kinase inhibitor downregulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 2004;10:7540–7546.10.1158/1078-0432.CCR-04-063215569984)| false
• Search Google Scholar
• Export Citation

Denton CP, Lindahl GE, Khan K, et al.. Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II transforming growth factor-β receptor (TβRIIδk). J Biol Chem 2005;280: 16053–16065.

• Crossref
• PubMed
Denton CP, Lindahl GE, Khan K, . Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II transforming growth factor-β receptor (TβRIIδk). J Biol Chem 2005;280: 16053–16065.1570885310.1074/jbc.M413134200)| false
• Search Google Scholar
• Export Citation

Yin JJ, Mohammad KS, Kakonen SM, et al.. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003;100: 10954–10959.

• Crossref
• PubMed
Yin JJ, Mohammad KS, Kakonen SM, . A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003;100: 10954–10959.10.1073/pnas.183097810012941866)| false
• Search Google Scholar
• Export Citation

Carducci MA, Padley RJ, Breul J, et al.. Effect of endothelin-A receptor blockade with atraxentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679–689.

• Crossref
• PubMed
Carducci MA, Padley RJ, Breul J, . Effect of endothelin-A receptor blockade with atraxentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679–689.10.1200/JCO.2003.04.17612586806)| false
• Search Google Scholar
• Export Citation

Nelson JB. Endothelin inhibition: novel therapy for prostate cancer. J Urol 2003;170:S65–S67.

• Crossref
• PubMed
Nelson JB. Endothelin inhibition: novel therapy for prostate cancer. J Urol 2003;170:S65–S67.1461041310.1097/01.ju.0000096372.07687.86)| false
• Search Google Scholar
• Export Citation

Guise TA, Kozlow WM, Heras-Herzig A, et al.. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 2005;5(Suppl 2):S46–53.

• Crossref
• PubMed
Guise TA, Kozlow WM, Heras-Herzig A, . Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 2005;5(Suppl 2):S46–53.10.3816/CBC.2005.s.00415807924)| false
• Search Google Scholar
• Export Citation

Hamaoka T, Madewell JE, Podoloff DA, et al.. Bone imaging in metastatic breast cancer. J Clin Oncol 2004;22: 2942–2953.

• Crossref
• PubMed
Hamaoka T, Madewell JE, Podoloff DA, . Bone imaging in metastatic breast cancer. J Clin Oncol 2004;22: 2942–2953.10.1200/JCO.2004.08.18115254062)| false
• Search Google Scholar
• Export Citation

Ward WG, Holsenbeck S, Dorey FJ, et al.. Metastatic disease of the femur: Surgical treatment. Clin Orthop Relat Res 2003;415(Suppl):S230–244.

• Crossref
• PubMed
Ward WG, Holsenbeck S, Dorey FJ, . Metastatic disease of the femur: Surgical treatment. Clin Orthop Relat Res 2003;415(Suppl):S230–244.10.1097/01.blo.0000093849.72468.8214600615)| false
• Search Google Scholar
• Export Citation

Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res 1989;249:256–264.

• PubMed
Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res 1989;249:256–264.)| false
• Search Google Scholar
• Export Citation

Samsani SR, Panikkar V, Venu KM, et al.. Breast cancer bone metastasis in femur: surgical considerations and reconstruction with Long Gamma Nail. Eur J Surg Oncol 2004; 30:993–997.

• Crossref
• PubMed
Samsani SR, Panikkar V, Venu KM, . Breast cancer bone metastasis in femur: surgical considerations and reconstruction with Long Gamma Nail. Eur J Surg Oncol 2004; 30:993–997.10.1016/j.ejso.2004.07.01515498647)| false
• Search Google Scholar
• Export Citation

Moholkar K, Mohan R, Grigoris P. The Long Gamma Nail for stabilisation of existing and impending pathological fractures of the femur: an analysis of 48 cases. Acta Orthop Belg 2004;70:429–434.

• PubMed
Moholkar K, Mohan R, Grigoris P. The Long Gamma Nail for stabilisation of existing and impending pathological fractures of the femur: an analysis of 48 cases. Acta Orthop Belg 2004;70:429–434.)| false
• Search Google Scholar
• Export Citation

Marco RA, Sheth DS, Boland PJ, et al.. Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease. J Bone Joint Surg Am 2000;82:642–651.

• Crossref
• PubMed
Marco RA, Sheth DS, Boland PJ, . Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease. J Bone Joint Surg Am 2000;82:642–651.10.2106/00004623-200005000-0000510819275)| false
• Search Google Scholar
• Export Citation

Benevenia J, Cyran FP, Biermann JS, et al.. Treatment of advanced metastatic lesions of the acetabulum using the saddle prosthesis. Clin Orthop Relat Res 2004;426: 23–31.

• Crossref
• PubMed
Benevenia J, Cyran FP, Biermann JS, . Treatment of advanced metastatic lesions of the acetabulum using the saddle prosthesis. Clin Orthop Relat Res 2004;426: 23–31.10.1097/01.blo.0000141387.03035.3e15346047)| false
• Search Google Scholar
• Export Citation

Redmond BJ, Biermann JS, Blasier RB. Interlocking intramedullary nailing of pathological fractures of the shaft of the humerus. J Bone Joint Surg Am 1996;78A:891–896.

• Crossref
• PubMed
Redmond BJ, Biermann JS, Blasier RB. Interlocking intramedullary nailing of pathological fractures of the shaft of the humerus. J Bone Joint Surg Am 1996;78A:891–896.10.2106/00004623-199606000-000128666607)| false
• Search Google Scholar
• Export Citation

Franck WM, Olivieri M, Jannasch O, Hennig FF. An expandable nailing system for the management of pathological humerus fractures. Arch Orthop Trauma Surg 2002;122: 400–405.

• Crossref
• PubMed
Franck WM, Olivieri M, Jannasch O, Hennig FF. An expandable nailing system for the management of pathological humerus fractures. Arch Orthop Trauma Surg 2002;122: 400–405.10.1007/s00402-002-0428-112228801)| false
• Search Google Scholar
• Export Citation

Clohisy DR, Le CT, Cheng EY. Evaluation of the feasibility of and results of measuring health-status changes in patients undergoing surgical treatment for skeletal metastases. J Orthop Res 2000;18:1–9.

• Crossref
• PubMed
Clohisy DR, Le CT, Cheng EY. Evaluation of the feasibility of and results of measuring health-status changes in patients undergoing surgical treatment for skeletal metastases. J Orthop Res 2000;18:1–9.10.1002/jor.110018010210716272)| false
• Search Google Scholar
• Export Citation

Talbot M, Turcotte RE, Isler M, et al.. Function and health status in surgically treated bone metastases. Clin Orthop Relat Res 2005;438:215–220.

• Crossref
• PubMed
Talbot M, Turcotte RE, Isler M, . Function and health status in surgically treated bone metastases. Clin Orthop Relat Res 2005;438:215–220.10.1097/01.blo.0000170721.07088.2e16131894)| false
• Search Google Scholar
• Export Citation

Dijstra S, Wiggers T, van Geel BN, Boxma H. Impending and actual pathological fractures in patients with bone metastases of the long bones: A retrospective study of 233 surgically treated fractures. Eur J Surg 1994;160:535–542.

• PubMed
Dijstra S, Wiggers T, van Geel BN, Boxma H. Impending and actual pathological fractures in patients with bone metastases of the long bones: A retrospective study of 233 surgically treated fractures. Eur J Surg 1994;160:535–542.)| false
• Search Google Scholar
• Export Citation

Goetz MP, Callstrom MR, Charboneau JW, et al.. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 2004;22:300–306.